oncometrix
DESCRIPTION
26-28 MAY, 2013 - FIRST ANNUAL YOUTH ENTREPRENEURSHIP AND INNOVATORS CONFERENCE IN RUSSIA. STARTUP VILLAGE - one of the most ambitious start-up conferences in Russia, organized by Skolkovo in cooperation with partners. The conference is the first this year and will be held annually. ONCOMETRIX is the first conference day's pitch session participant in the Life Science pavillion.TRANSCRIPT
Prostate Cancer – Most Common Cancer in Men
More than 50% of men over 50 years old have prostatic symptoms
Current prostate cancer diagnostics is not efficient:
• PSA – widely used primary diagnostic blood test
• 70% false alarm
• 25% false-negative (men with proven prostate cancer show normal PSA test result)
• BIOPSY– highly invasive final diagnostic work-up
• 25% false negative results by multiple biopsy
Non-invasive and cost-effective primary prostate cancer diagnostic method is needed
BIOPSY
Market size
350 million men globally have prostatic symptoms
Target market sectors:
• Precise diagnostic test for professional use (Point-Of-Care-Device): equal to PSA test market with 45 million tests yearly
à 1.8 billion USD annually
• Primary test for home use (Over-The-Counter): 20% market penetration and 30 USD test kit price
à 2.1 billion USD annually
Potential market: 3.9 billion USD annually
Current Status
A set of non-protein biomarkers was identified in prostate tissue samples from:
• 35 healthy controls • 45 men with Benign Prostatic Hyperplasia • 60 men with Prostate Cancer
Patent Application is filed on 45 biomarkers of prostate cancer (GB1307520.5) Further IP is to cover specific designs of diagnostic devices Work in progress to translate tissue results into prostatic and seminal fluids
Optimising detection methods for selected biomarkers in prostatic and seminal fluids
New Method of Prostate Cancer Diagnostics
We identified a group of novel non-protein biomarkers for prostate cancer in prostatic secretion and seminal fluid
On the basis of the proprietary biomarkers team is developing 2 types of novel tests for prostate cancer:
a. Precise non-invasive diagnostic device for ���professional use
b. Simple affordable prostate health test for home use (similar to a pregnancy test)
Two types of novel tests are being developed: for professional and home use
Competitive Advantages
Advantages of the Oncometrix tests:
• Measurement of several biomarkers at the same time increasing diagnostic accuracy significantly exceeding PSA
• Non-invasive
• Affordable
• Easy-to-use
• Use of a miniature portable device
• Immediate result
High accuracy, easiness of use and cost-efficiency
Marker 1 Marker 2
Tissue type: 1-Normal 2-BPH 3-PCa
Con
cent
ratio
n Tissue type
Competitive Analysis
Promising performance to detect prostate cancer
Prostate cancer diagnostic test PSA Oncometrix
Accuracy 50 % 99 %
Sensitivity 43-73 % 98 %
Specificity 56-97 % 99 %
Positive Predictive Value* 17-30 % 74 %
*- 65-69 years old
Stage 1: Proof of concept
• £300K investment
• 20% of equity • 18 months
• Selection of markers • Detection methods
optimization • IP development and
protection, patenting
Stage 2: Product
development
• £3M investment
• 24 months
• Device development and clinical trials
Stage 3: Commercialization
• £5 M investment
• 36 months
• Alternatively: self-funded scale-up
• Business model: license sale and device manufacturing
Exit
• Trade sale at £60-120M
• in year 6
• Alternatively: exit in year 4 (after regulatory approvals, Stage 2), at £30-50M
Project Timeline and Finance
Total investments: £8.3 million Duration: 6 years Sales: £60-120 million
The Team��� Dedicated professionals from research and business areas, 8PhDs, 4 High-Tec entrepreneurs
Prof. Vladimir Zaichick, FRSC, Chief Scientist over 50 years experience in medicinal physics and diagnostic method development. World leading authority in microelement composition of human tissues
Dr Dmitry Soloviev, MRSC, Technology Adviser over 20 years experience in development and production of diagnostic radiopharmaceuticals. Cancer Research UK.
Dr Maxim Rossmann, Science Director over 10 years experience in development of Targeted Cancer Therapies and screening tests, enzymatic methods. Cambridge University.
Dr Mikhail Lomonosov, Managing Director over 12 years experience in Cancer Biomarkers and Molecular Therapies, Cambridge University.
Mrs Irina Soltamova Solovyev, Finance Director over 15 years experience in financial and business consulting and auditing.
Dr Istvan Boros, MRSC, Patent Specialist 8 years experience as patent expert. Cambridge University
Dr Pavel Shashkov, Business Adviser over 20 years experience in high-tech business development. Cambridge Nanolitic
Dr Dmitry Lebedev, MD, Urology Practitioner More than 10 years experience in clinical urology, participation in clinical trials.